Jun Yan1, Xiaolin Wang, Shengli Chen. 1. Jinan City Hospital for Skin Diseases Prevention and Treatment, Jinan, 250001, China.
Abstract
BACKGROUND: Terbinafine is an effective antimicrobial agent against dermatophytes, cryptococcus and other fungi. It is the preferred drug to treat onychomycosis. However, severe acute hepatitis from oral terbinafine administration has been recently reported. AIM: To describe a representative case, and review the literature regarding the best evidence on treatment and prognosis of severe acute hepatitis caused by oral terbinafine. METHODS: The literature was searched for publications on severe hepatitis caused by terbinafine using MEDLINE, China Biology Medicine Disc, and the VIP Medical Information Resource System. Related references were searched manually. RESULTS: Seventeen English and three Chinese references of case reports were included after eliminating duplicate publications. No randomized control studies were found. Liver enzyme levels were found to have been increased significantly. Abdominal ultrasound demonstrated cholestasis. CONCLUSIONS: Severe acute liver injury is a known, but unusual complication of terbinafine exposure. The prognosis is often good with appropriate treatment. Liver function assessment before treatment and periodic monitoring 4-6 weeks after initiation of treatment is recommended.
BACKGROUND:Terbinafine is an effective antimicrobial agent against dermatophytes, cryptococcus and other fungi. It is the preferred drug to treat onychomycosis. However, severe acute hepatitis from oral terbinafine administration has been recently reported. AIM: To describe a representative case, and review the literature regarding the best evidence on treatment and prognosis of severe acute hepatitis caused by oral terbinafine. METHODS: The literature was searched for publications on severe hepatitis caused by terbinafine using MEDLINE, China Biology Medicine Disc, and the VIP Medical Information Resource System. Related references were searched manually. RESULTS: Seventeen English and three Chinese references of case reports were included after eliminating duplicate publications. No randomized control studies were found. Liver enzyme levels were found to have been increased significantly. Abdominal ultrasound demonstrated cholestasis. CONCLUSIONS: Severe acute liver injury is a known, but unusual complication of terbinafine exposure. The prognosis is often good with appropriate treatment. Liver function assessment before treatment and periodic monitoring 4-6 weeks after initiation of treatment is recommended.
Authors: R Baran; M Feuilhade; P Combernale; A Datry; S Goettmann; P Pietrini; C Viguie; G Badillet; C Larnier; J Czernielewski Journal: Br J Dermatol Date: 2000-06 Impact factor: 9.302
Authors: Sanne Kreijkamp-Kaspers; Kate Hawke; Linda Guo; George Kerin; Sally Em Bell-Syer; Parker Magin; Sophie V Bell-Syer; Mieke L van Driel Journal: Cochrane Database Syst Rev Date: 2017-07-14
Authors: E P Garvey; W J Hoekstra; W R Moore; R J Schotzinger; L Long; M A Ghannoum Journal: Antimicrob Agents Chemother Date: 2015-01-20 Impact factor: 5.191
Authors: Robert John Fontana; Elizabeth Theresa Cirulli; Jiezhun Gu; David Kleiner; David Ostrov; Elizabeth Phillips; Ryan Schutte; Huiman Barnhart; Naga Chalasani; Paul Brent Watkins; Jay H Hoofnagle Journal: J Hepatol Date: 2018-08-21 Impact factor: 25.083
Authors: Francislene J Martins; César A Caneschi; Mônica P Senra; Gustavo S G Carvalho; Adilson D da Silva; Nádia R B Raposo Journal: ScientificWorldJournal Date: 2017-10-26
Authors: Julia K Christenson; Gregory M Peterson; Mark Naunton; Mary Bushell; Sam Kosari; Kavya E Baby; Jackson Thomas Journal: J Fungi (Basel) Date: 2018-07-24